https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51125 Tue 22 Aug 2023 15:51:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41980 Tue 16 Aug 2022 15:48:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52824 Mon 30 Oct 2023 09:18:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46149 40 and Aβ₄₂ concentrations were measured using the ultrasensitive Single Molecule Array (Simoa) assay in 95 cognitively normal elderly individuals, who have all undergone PET to assess brain Aβ deposition. Based on the standard uptake value ratios (SUVR) obtained from PET imaging, using the tracer ¹⁸F-Florbetaben, plasma Aβ was compared between 32 participants assessed to have low brain Aβ load (Aβ–, SUVR <1.35) and 63 assessed to have high brain Aβ load (Aβ+, SUVR ≥1.35). Results: Plasma Aβ₄₂/Aβ₄₀ ratios were lower in the Aβ+ group compared to the Aβ–group. Plasma Aβ₄₀ and Aβ₄₂ levels were not significantly different between Aβ–and Aβ+ groups, although a trend of higher plasma Aβ₄₀ was observed in the Aβ+ group. Additionally, plasma Aβ₄₂/Aβ₄₀ ratios along with the known AD risk factors, age and APOE ɛ4 status, resulted in Aβ+ participants being distinguished from Aβ–participants based on an area under the receiver operating characteristic curve shown to be 78%. Conclusion: Plasma Aβ ratios in this study are a potential biomarker for brain Aβ deposition and therefore, for preclinical AD. However, this method to measure plasma Aβ needs further development to increase the accuracy of this promising AD blood biomarker.]]> Fri 11 Nov 2022 18:51:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53590 PD >NG, p=0.0046). Post-hoc analysis indicated significantly higher plasma NfL levels in the T2D [12.4 (5.21) pg/mL] group than in the PD [10.2 (4.13) pg/mL] and NG [8.37 (5.65) pg/mL] groups. The relationship between diabetes status and NfL remained significant after adjusting for age, sex, BMI, HOMA-IR and physical activity (adjusted r2 = 0.271, p = 0.035). Conclusions: These results show biomarker evidence of neurodegeneration in adults at risk or with T2D. Larger sample size and longitudinal analysis are required to better understand the application of NfL in people with risk and overt T2D.]]> Fri 08 Dec 2023 15:47:18 AEDT ]]>